Joshua Zaritsky, MD
Pediatric Nephrology · Phoenix, AZNPI 1396871844
Payments from drug & device makers
Across 585 payments — averaging $886.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$177K
- Ultragenyx Pharmaceutical Inc.$82K
- Kyowa Kirin, Inc.$71K
- Alnylam Pharmaceuticals Inc.$59K
- Travere Therapeutics, Inc.$42K
- Kaneka Medical America LLC$35K
- plus $55K from 20 others
Across 4 payments — averaging $1199.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$5K
What the payments were for
- Consulting fees$82,24817%
- Speaking & faculty fees$355,79373%
- Travel & lodging$36,0477%
- Food & beverage$10,3652%
- Education$2,4521%
- Entertainment$1630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 149 | $176,758 |
| Ultragenyx Pharmaceutical Inc. | 108 | $81,519 |
| Kyowa Kirin, Inc. | 80 | $70,581 |
| Alnylam Pharmaceuticals Inc. | 67 | $58,769 |
| Travere Therapeutics, Inc. | 69 | $41,539 |
| Kaneka Medical America LLC | 11 | $35,078 |
| Rhythm Pharmaceuticals, Inc. | 27 | $27,089 |
| Nxstage Medical, Inc. | 7 | $4,882 |
| AstraZeneca | 15 | $4,653 |
| Vertex | 6 | $4,200 |
| Novo Nordisk | 10 | $4,051 |
| Vifor Pharma, Inc. | 3 | $4,000 |
| Leadiant Biosciences, Inc. | 8 | $2,720 |
| Bayer | 1 | $2,030 |
| Aurinia Pharma U.S., Inc. | 10 | $301 |
| Novartis | 1 | $133 |
| Recordati_rare_diseases_inc. | 3 | $118 |
| Hollister Incorporated | 1 | $91 |
| Quanta Dialysis Technologies Inc | 1 | $64 |
| Novo Nordisk Health Care AG | 1 | $50 |
| Potrero Medical, Inc. | 1 | $45 |
| Baxter Healthcare | 2 | $38 |
| Mallinckrodt Enterprises LLC | 1 | $33 |
| Azurity Pharmaceuticals, Inc. | 1 | $28 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Biomarin Pharmaceutical Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCYSBI$161,737
- CRYSVITA$81,073
- OXLUMO$51,322
- Imcivree$21,751
- (815) Thiola$20,101
- Cryvista$7,918
- NXSTAGE SYSTEM ONE$4,690
- Liposober$4,500
- Strensiq$4,020
- Cystaran$2,500
- Kerendia$2,030
- LIPOSORBER$2,000
- SOLIRIS$184
- ULTOMIRIS$150
- Fabhalta$133
How this compares
Too few pediatric nephrology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pediatric nephrology in Phoenix
- Anjali NayakPhoenix$59K
- Emilia Maria CadizPhoenix$6K
- Ronald HoggPhoenix$5K
- Stephanie HsiehPhoenix$604
- Karen PapezPhoenix$584
- Katherine PerryPhoenix$346
- Kelly BenedictPhoenix$323
- Ashley GefenPhoenix$230
- Martin TurmanPhoenix$201
- Sheena SharmaPhoenix$101
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.